Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
K Tokushige, K Ikejima, M Ono, Y Eguchi… - Journal of …, 2021 - Springer
Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only
in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic …
in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic …
Nonalcoholic steatohepatitis: a review
Importance Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic
fatty liver disease (NAFLD) and is associated with disease progression, development of …
fatty liver disease (NAFLD) and is associated with disease progression, development of …
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
Update on NAFLD genetics: from new variants to the clinic
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver diseases in high-
income countries and the burden of NAFLD is increasing at an alarming rate. The risk of …
income countries and the burden of NAFLD is increasing at an alarming rate. The risk of …
Steatotic liver disease: pathophysiology and emerging pharmacotherapies
M Kokkorakis, E Muzurović, Š Volčanšek… - Pharmacological …, 2024 - Elsevier
Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype.
Consequently, the metabolic dysfunction-associated steatotic liver disease …
Consequently, the metabolic dysfunction-associated steatotic liver disease …
[PDF][PDF] Role of cholesterol‐associated steatohepatitis in the development of NASH
CL Horn, AL Morales, C Savard… - Hepatology …, 2022 - Wiley Online Library
The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and NAFLD‐related
cirrhosis in the United States and globally highlights the need to better understand the …
cirrhosis in the United States and globally highlights the need to better understand the …
Treatments for NAFLD: state of art
A Mantovani, A Dalbeni - International journal of molecular sciences, 2021 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) is to date the most common chronic liver disease
in clinical practice and, consequently, a major health problem worldwide. It affects …
in clinical practice and, consequently, a major health problem worldwide. It affects …
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
H Li, XH Yu, X Ou, XP Ouyang, CK Tang - Progress in lipid research, 2021 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) is a quickly emerging global health problem
representing the most common chronic liver disease in the world. Atherosclerotic …
representing the most common chronic liver disease in the world. Atherosclerotic …
Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр
ВВ Кухарчук, МВ Ежов, ИВ Сергиенко… - Атеросклероз и …, 2020 - cyberleninka.ru
Согласно данным Росстата, смертность от заболеваний сердечно-сосудистой
системы (ССЗ) в Российской Федерации в 2017 г. составила 587, 6 случая на 100 тыс …
системы (ССЗ) в Российской Федерации в 2017 г. составила 587, 6 случая на 100 тыс …
[HTML][HTML] Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic …
SA Harrison, G Neff, CD Guy, MR Bashir, AH Paredes… - Gastroenterology, 2021 - Elsevier
Background & Aims Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits
bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week …
bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week …